Eli Lilly and Company announced that it has completed the acquisition of SGX Pharmaceuticals, Inc, a San Diego-based biotechnology company focused on drug discovery and development in the area of oncology. The completion of the deal followed Special Stockholders Meeting, in which a majority of SGX stockholders voted in favour of the merger agreement with Lilly.
Under the agreement, Lilly has acquired all of the outstanding shares of SGX common stock at a price of $3.00 per share. All other closing conditions have also been met.
The deal, valued at a total purchase price of $64 million, will allow Lilly to integrate SGX's structure-guided drug discovery platform into its drug discovery efforts. It will also give Lilly access to FAST, SGX's fragment-based, protein structure guided drug discovery technology, and to a portfolio of pre-clinical oncology compounds focused on a number of high-value kinase targets.
"We are pleased to complete the acquisition of SGX and are excited to bring the scientific and technological expertise of SGX into Lilly's research organization," remarked Steven M Paul, executive vice-president, science and technology for Lilly. "We will leverage the combined resources of both companies to strengthen our structural biology capabilities and seek out innovative therapies for patients."
The impact of the acquisition, including a one-time charge to earnings for acquired in-process research and development, will be reflected in Lilly's third quarter 2008 financial results.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.